Clinical Trials in Saint-Mandé, France
1 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575
Recruiting
Not Applicable
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
Institut Curie60 enrolled6 locationsNCT06349512
Recruiting
PRostate Olaparib Real World Evidence Study
Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Not Applicable
Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
Metastatic Triple-Negative Breast Carcinoma
UNICANCER472 enrolled51 locationsNCT06505018
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 3
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris1,210 enrolled23 locationsNCT03819101
Recruiting
Phase 3
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Metastatic Non-squamous Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris1,166 enrolled37 locationsNCT05692999
Recruiting
Phase 3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
UNICANCER300 enrolled90 locationsNCT04916613